多发性硬化症的临床前模型：更好疗法的优点和局限性

Title:Preclinical Models of Multiple Sclerosis: Advantages and Limitations Towards Better Therapies

Volume: 23 Issue: 14

Author(s): Alessandro Didonna

Affiliation:

关键词: 多发性硬化症，脱髓鞘，实验性自身免疫性脑脊髓炎，自身免疫，cuprizone，卵磷脂，泰勒的小鼠脑脊髓炎病毒、鼠肝炎病毒。

摘要: Multiple sclerosis (MS) is a disease of the central nervous system (CNS) with an unknown etiology. MS complex pathophysiology—characterized by CNS inflammation, demyelination and axonal injury—has made its modeling in experimental systems particularly problematic. Moreover, the evidence that MS does not naturally occur in other species has further complicated MS preclinical studies. Through the years, several MS in vivo models have been developed. Experimental autoimmune encephalomyelitis (EAE) represents the most widely used MS experimental model and relies upon the autoimmune paradigm to explore MS neuropathology. Although EAE has been instrumental in understanding the molecular events which take place upon neuroinflammation, not all MS hallmarks can be efficiently shaped within this conceptual frameshift. Thus, alternative models of CNS demyelination have been characterized, either based on viral infection or neurotoxin administration. However imperfect, these models have greatly improved our knowledge of the immune system's function in health and disease. On the other side, their intrinsic distance from MS has often led to misinterpreting and overestimating the data gleaned from these experimental systems. In this review, each model will be discussed in the light of its potentiality to mimic MS and translate the most promising therapies to patients. In addition, we will address how new genomic technologies can help improve the existing models.

Cite this article as:

Alessandro Didonna , Preclinical Models of Multiple Sclerosis: Advantages and Limitations Towards Better Therapies, Current Medicinal Chemistry 2016; 23 (14) . https://dx.doi.org/10.2174/0929867323666160406121218